ATNM
Price:
$1.76
Market Cap:
$54.83M
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple...[Read more]
Industry
Biotechnology
IPO Date
2012-12-27
Stock Exchange
AMEX
Ticker
ATNM
According to Actinium Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 8.95. This represents a change of -7.30% compared to the average of 9.66 of the last 4 quarters.
The mean historical Current Ratio of Actinium Pharmaceuticals, Inc. over the last ten years is 6.45. The current 8.95 Current Ratio has changed 13.78% with respect to the historical average. Over the past ten years (40 quarters), ATNM's Current Ratio was at its highest in in the June 2021 quarter at 21.47. The Current Ratio was at its lowest in in the December 2014 quarter at 0.78.
Average
6.45
Median
5.35
Minimum
0.78
Maximum
13.62
Discovering the peaks and valleys of Actinium Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 635.57%
Maximum Annual Current Ratio = 13.62
Minimum Annual Increase = -38.18%
Minimum Annual Current Ratio = 0.78
Year | Current Ratio | Change |
---|---|---|
2023 | 9.21 | -11.73% |
2022 | 10.44 | -10.47% |
2021 | 11.66 | -14.39% |
2020 | 13.62 | 621.46% |
2019 | 1.89 | -20.12% |
2018 | 2.36 | -38.18% |
2017 | 3.82 | -22.81% |
2016 | 4.95 | -13.71% |
2015 | 5.74 | 635.57% |
2014 | 0.78 | -0.62% |
The current Current Ratio of Actinium Pharmaceuticals, Inc. (ATNM) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
10.44
5-year avg
9.36
10-year avg
6.45
Actinium Pharmaceuticals, Inc.’s Current Ratio is greater than MiNK Therapeutics, Inc. (0.93), greater than Affimed N.V. (2.71), greater than ImmunoGen, Inc. (5.47), greater than Adaptimmune Therapeutics plc (3.09), greater than Sangamo Therapeutics, Inc. (1.03), greater than Rigel Pharmaceuticals, Inc. (1.62), greater than Fortress Biotech, Inc. (1.37), greater than Reviva Pharmaceuticals Holdings, Inc. (0.41), greater than CTI BioPharma Corp. (1.27), less than Ocuphire Pharma, Inc. (10.68), greater than Annovis Bio, Inc. (1.24), greater than Cassava Sciences, Inc. (4.07), greater than Axsome Therapeutics, Inc. (2.48), greater than Seres Therapeutics, Inc. (1.38), greater than Reviva Pharmaceuticals Holdings, Inc. (0.41), greater than Eyenovia, Inc. (0.43), greater than Cognition Therapeutics, Inc. (3.07), greater than TransCode Therapeutics, Inc. (1.25), less than Kodiak Sciences Inc. (10.59), greater than Exelixis, Inc. (3.93), greater than TG Therapeutics, Inc. (3.58), less than Viking Therapeutics, Inc. (36.47), greater than Madrigal Pharmaceuticals, Inc. (5.98), greater than BioXcel Therapeutics, Inc. (2.35),
Company | Current Ratio | Market cap |
---|---|---|
0.93 | $28.82M | |
2.71 | $49.79M | |
5.47 | $8.73B | |
3.09 | $204.51M | |
1.03 | $362.30M | |
1.62 | $247.56M | |
1.37 | $47.68M | |
0.41 | $33.39M | |
1.27 | $1.20B | |
10.68 | $31.74M | |
1.24 | $113.96M | |
4.07 | $1.24B | |
2.48 | $4.19B | |
1.38 | $137.42M | |
0.41 | $36.43M | |
0.43 | $44.32M | |
3.07 | $19.04M | |
1.25 | $8.89M | |
10.59 | $205.20M | |
3.93 | $9.79B | |
3.58 | $3.77B | |
36.47 | $7.04B | |
5.98 | $7.23B | |
2.35 | $26.28M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Actinium Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Actinium Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Actinium Pharmaceuticals, Inc.'s Current Ratio?
How is the Current Ratio calculated for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the highest Current Ratio for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the 3-year average Current Ratio for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the 5-year average Current Ratio for Actinium Pharmaceuticals, Inc. (ATNM)?
How does the current Current Ratio for Actinium Pharmaceuticals, Inc. (ATNM) compare to its historical average?